Given that other neoadjuvant immunotherapy studies have not incorporated chemotherapy, this study investigated the efficacy and safety of combining PD-1 antibody with chemotherapy and vascular endothelial growth factor (VEGF) antibody in locally advanced dMMR/MSI CRC.20 This evidence concerns the gene VEGFA and colorectal carcinoma.